These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38318822)

  • 1. Treatment strategies for patients with HER2-positive gastric cancer.
    Wang F; Ba Y
    Cancer Biol Med; 2024 Feb; 20(12):934-41. PubMed ID: 38318822
    [No Abstract]   [Full Text] [Related]  

  • 2. Metabolomic therapy response prediction in pretherapeutic tissue biopsies for trastuzumab in patients with HER2-positive advanced gastric cancer.
    Kunzke T; Hölzl FT; Prade VM; Buck A; Huber K; Feuchtinger A; Ebert K; Zwingenberger G; Geffers R; Hauck SM; Haffner I; Luber B; Lordick F; Walch A
    Clin Transl Med; 2021 Sep; 11(9):e547. PubMed ID: 34586736
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer.
    Müller V; Clemens M; Jassem J; Al-Sakaff N; Auclair P; Nüesch E; Holloway D; Shing M; Bang YJ
    BMC Cancer; 2018 Mar; 18(1):295. PubMed ID: 29544445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.
    Shitara K; Iwata H; Takahashi S; Tamura K; Park H; Modi S; Tsurutani J; Kadowaki S; Yamaguchi K; Iwasa S; Saito K; Fujisaki Y; Sugihara M; Shahidi J; Doi T
    Lancet Oncol; 2019 Jun; 20(6):827-836. PubMed ID: 31047804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?
    Roviello G; Aprile G; D'Angelo A; Iannone LF; Roviello F; Polom K; Mini E; Catalano M
    Gastric Cancer; 2021 Jul; 24(4):765-779. PubMed ID: 33742317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hopes and failures in front-line advanced HER2-positive gastric cancer therapy.
    Kong F; Yao Y; Deng R; Li X; Jia Y
    Anticancer Drugs; 2021 Aug; 32(7):675-680. PubMed ID: 33929993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer.
    Wakatsuki T; Yamamoto N; Sano T; Chin K; Kawachi H; Takahari D; Ogura M; Ichimura T; Nakayama I; Osumi H; Matsushima T; Suenaga M; Shinozaki E; Hiki N; Ishikawa Y; Yamaguchi K
    J Gastroenterol; 2018 Nov; 53(11):1186-1195. PubMed ID: 29633013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
    Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
    BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer.
    Barok M; Le Joncour V; Martins A; Isola J; Salmikangas M; Laakkonen P; Joensuu H
    Cancer Lett; 2020 Mar; 473():156-163. PubMed ID: 31904483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalized therapeutic strategies in HER2-driven gastric cancer.
    Ughetto S; Migliore C; Pietrantonio F; Apicella M; Petrelli A; D'Errico L; Durando S; Moya-Rull D; Bellomo SE; Rizzolio S; Capelôa T; Ribisi S; Degiuli M; Reddavid R; Rapa I; Fumagalli U; De Pascale S; Ribero D; Baronchelli C; Sgroi G; Rausa E; Baiocchi GL; Molfino S; Manenti S; Bencivenga M; Sacco M; Castelli C; Siena S; Sartore-Bianchi A; Tosi F; Morano F; Raimondi A; Prisciandaro M; Gloghini A; Marsoni S; Sottile A; Sarotto I; Sapino A; Marchiò C; Cassoni P; Guarrera S; Corso S; Giordano S
    Gastric Cancer; 2021 Jul; 24(4):897-912. PubMed ID: 33755862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2-targeted therapies in gastric cancer.
    Zhu Y; Zhu X; Wei X; Tang C; Zhang W
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188549. PubMed ID: 33894300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction of
    Guo X; Zhou N; Chen Z; Liu T; Xu X; Lei X; Shen L; Gao J; Yang Z; Zhu H
    Gastric Cancer; 2020 Jul; 23(4):614-626. PubMed ID: 31919745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604).
    Saeki H; Oki E; Kashiwada T; Arigami T; Makiyama A; Iwatsuki M; Narita Y; Satake H; Matsuda Y; Sonoda H; Shimokawa M; Maehara Y;
    Eur J Cancer; 2018 Dec; 105():41-49. PubMed ID: 30391779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type.
    Xu C; Liu Y; Jiang D; Li Q; Ge X; Zhang Y; Huang J; Su J; Ji Y; Hou J; Lu S; Hou Y; Liu T
    Oncotarget; 2017 May; 8(20):33185-33196. PubMed ID: 28388541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors of trastuzumab-based chemotherapy in HER2 positive advanced gastric cancer: a single-center prospective observational study.
    Li Q; Li H; Jiang H; Feng Y; Cui Y; Wang Y; Ji Y; Yu Y; Li W; Xu C; Yu S; Zhuang R; Liu T
    Clin Transl Oncol; 2018 Jun; 20(6):695-702. PubMed ID: 29168107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABP 980: A Trastuzumab Biosimilar.
    Dhillon S
    BioDrugs; 2018 Oct; 32(5):511-514. PubMed ID: 30264234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer.
    Yagi S; Wakatsuki T; Yamamoto N; Chin K; Takahari D; Ogura M; Ichimura T; Nakayama I; Osumi H; Shinozaki E; Suenaga M; Fujisaki J; Ishikawa Y; Yamaguchi K; Namikawa K; Horiuchi Y
    Gastric Cancer; 2019 May; 22(3):518-525. PubMed ID: 30328533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study.
    Dijksterhuis WPM; Verhoeven RHA; Meijer SL; Slingerland M; Haj Mohammad N; de Vos-Geelen J; Beerepoot LV; van Voorthuizen T; Creemers GJ; van Oijen MGH; van Laarhoven HWM
    Gastric Cancer; 2020 Jul; 23(4):579-590. PubMed ID: 31927675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.
    Pietrantonio F; Fucà G; Morano F; Gloghini A; Corso S; Aprile G; Perrone F; De Vita F; Tamborini E; Tomasello G; Gualeni AV; Ongaro E; Busico A; Giommoni E; Volpi CC; Laterza MM; Corallo S; Prisciandaro M; Antista M; Pellegrinelli A; Castagnoli L; Pupa SM; Pruneri G; de Braud F; Giordano S; Cremolini C; Di Bartolomeo M
    Clin Cancer Res; 2018 Mar; 24(5):1082-1089. PubMed ID: 29208673
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and Safety of Trastuzumab Biosimilar (CT-P6) Compared With Reference Trastuzumab in Patients With HER2-positive Advanced Gastric Cancer: A Retrospective Analysis.
    Park JH; Yeo JH; Kim YS; Park I; Ahn HK; Cho EK; Shin DB; Yang JY; Kim HS; Lee WK; Sym SJ
    Am J Clin Oncol; 2022 Feb; 45(2):61-65. PubMed ID: 34991106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.